Investigating ways to reduce nerve damage from cisplatin chemotherapy
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system
This study is looking at how to protect the nervous system from the harmful side effects of cisplatin, a chemotherapy drug, so that patients can have a better quality of life during their cancer treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11059724 on NIH RePORTER |
What this research studies
This research focuses on the harmful effects of cisplatin, a common chemotherapy drug, on the nervous system, leading to issues like cognitive impairment and neuropathy. The study aims to explore how blocking specific pathways in nerve cells can prevent these side effects. By using small molecule inhibitors, the researchers hope to protect neurons from damage caused by cisplatin, potentially improving the quality of life for patients undergoing cancer treatment. The approach involves both laboratory experiments and potential future clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are women undergoing treatment for ovarian cancer who are experiencing cognitive impairment or nerve damage due to cisplatin.
Not a fit: Patients who are not receiving cisplatin or those with pre-existing severe neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that alleviate debilitating nerve-related side effects of chemotherapy, improving patients' quality of life.
How similar studies have performed: Previous research has shown promise in using similar approaches to mitigate chemotherapy-induced nerve damage, indicating potential for success in this area.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Bota, Daniela Annenelie — University of California-Irvine
- Study coordinator: Bota, Daniela Annenelie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.